Literature DB >> 7559743

Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus X protein and hepatocarcinogenesis.

S Takada1, N Tsuchida, M Kobayashi, K Koike.   

Abstract

The X gene of the hepatitis B virus codes for a small basic protein and is able to transactivate viral and cellular genes, although the X protein exhibits no DNA-binding activity. The mechanism of transactivation by X protein has been suggested to be via protein-protein interaction(s). We first demonstrated that X protein had amino acid sequences homologous to the functionally essential domain of Kunitz-type serine protease inhibitors and that those sequences were indispensable for the transactivation function. We demonstrated that X protein exhibited an inhibitor activity against hepatic serine proteases, and subsequently found that the protein activated X gene transcription in HepG2 cells and that the X responsive element was localized in the minimal promoter of the X gene. In contrast, the tumor-suppressor gene p53, but not mutant p53, remarkably reduced transcription from the minimal promoter. This p53 repression on the X gene promoter was cancelled by X gene co-expression, probably indicating that the X protein disrupts the p53 tumor suppressor function in the nucleus. All data suggest that X protein leads to transactivation of cellular oncogenes by preventing an interaction between p53 and cellular transcription factor(s) consisting of the basal transcriptional machinery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559743     DOI: 10.1007/bf01197776

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  47 in total

1.  An internal domain of the hepatitis B virus X antigen is necessary for transactivating activity.

Authors:  S E Ritter; T M Whitten; A T Quets; R H Schloemer
Journal:  Virology       Date:  1991-06       Impact factor: 3.616

2.  trans-activation of viral enhancers by the hepatitis B virus X protein.

Authors:  D F Spandau; C H Lee
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

3.  Rearrangement of the p53 gene in human osteogenic sarcomas.

Authors:  H Masuda; C Miller; H P Koeffler; H Battifora; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

4.  Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication.

Authors:  R Colgrove; G Simon; D Ganem
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

5.  A transcription initiation site for the hepatitis B virus X gene is directed by the promoter-binding protein.

Authors:  K Yaginuma; I Nakamura; S Takada; K Koike
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

6.  Hepatitis B virus integration in hepatocellular carcinoma DNA: duplication of cellular flanking sequences at the integration site.

Authors:  K Yaginuma; M Kobayashi; E Yoshida; K Koike
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

7.  Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors.

Authors:  E Seto; P J Mitchell; T S Yen
Journal:  Nature       Date:  1990-03-01       Impact factor: 49.962

8.  Wild-type p53 binds to the TATA-binding protein and represses transcription.

Authors:  E Seto; A Usheva; G P Zambetti; J Momand; N Horikoshi; R Weinmann; A J Levine; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

9.  State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases.

Authors:  C Bréchot; M Hadchouel; J Scotto; M Fonck; F Potet; G N Vyas; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

10.  X protein of hepatitis B virus resembles a serine protease inhibitor.

Authors:  S Takada; K Koike
Journal:  Jpn J Cancer Res       Date:  1990-12
View more
  8 in total

1.  Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis.

Authors:  X W Wang
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

Review 2.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

Review 3.  Hepatitis B virus and hepatocellular carcinoma.

Authors:  P Arbuthnot; M Kew
Journal:  Int J Exp Pathol       Date:  2001-04       Impact factor: 1.925

Review 4.  Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma.

Authors:  M A Feitelson; L X Duan
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

5.  DDB2 induces nuclear accumulation of the hepatitis B virus X protein independently of binding to DDB1.

Authors:  A Nag; A Datta; K Yoo; D Bhattacharyya; A Chakrabortty; X Wang; B L Slagle; R H Costa; P Raychaudhuri
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Viral resistance in hepatitis B: prevalence and management.

Authors:  Fred Poordad; Grace M Chee
Journal:  Curr Gastroenterol Rep       Date:  2010-02

Review 7.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

Review 8.  RNAi for treating hepatitis B viral infection.

Authors:  Yong Chen; Guofeng Cheng; Ram I Mahato
Journal:  Pharm Res       Date:  2007-12-12       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.